Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
J Hum Genet. 2018 Feb;63(2):133-143. doi: 10.1038/s10038-017-0349-z. Epub 2017 Oct 11.
Current deep-sequencing technology provides a mass of nucleotide variations associated with human genetic disorders to accelerate the identification of causative mutations. To understand the etiology of genetic disorders, reverse genetics in human cultured cells is a useful approach for modeling a disease in vitro. However, gene targeting in human cultured cells is difficult because of their low activity of homologous recombination. Engineered endonucleases enable enhancement of the local activation of DNA repair pathways at the human genome target site to rewrite the desired sequence, thereby efficiently generating disease-modeling cultured cell clones. These edited cells can be used to explore the molecular functions of a causative gene product to uncover the etiological mechanisms. The correction of mutations in patient cells using genome editing technology could contribute to the development of unique gene therapies. This technology can also be applied to screening causative mutations. Rare genetic disorders and non-exonic mutation-caused diseases remain frontier in the field of human genetics as it is difficult to validate whether the extracted nucleotide variants are mutation or polymorphism. When isogenic human cultured cells with a candidate variant reproduce the pathogenic phenotypes, it is confirmed that the variant is a causative mutation.
目前的高通量测序技术提供了大量与人类遗传疾病相关的核苷酸变异,以加速致病突变的鉴定。为了了解遗传疾病的病因,在人培养细胞中进行反向遗传学是体外模拟疾病的一种有用方法。然而,由于同源重组活性低,人培养细胞中的基因靶向非常困难。工程内切酶可增强人类基因组靶位点处 DNA 修复途径的局部激活,从而重写所需序列,从而有效地生成疾病建模培养细胞克隆。这些编辑后的细胞可用于探索致病基因产物的分子功能,以揭示发病机制。利用基因组编辑技术纠正患者细胞中的突变可能有助于开发独特的基因治疗方法。该技术还可应用于筛选致病突变。罕见的遗传疾病和非外显子突变引起的疾病仍然是人类遗传学领域的前沿,因为很难验证提取的核苷酸变异是突变还是多态性。当候选变异的同基因人培养细胞再现致病表型时,即可确认该变异是致病突变。